Stefanie Dimmeler, Andreas M. Zeiher, Michael D. Schneider
J Clin Invest.
2005;
115(3):572–583
doi:10.1172/JCI24283
This article Copyright © 2005, The American Society for Clinical Investigation
Abstract
|
Full text
|
PDF
I
n humans, the biological limitations to cardiac regenerative growth create both a clinical imperative — to offset cell death in acute ischemic injury and chronic heart failure — and a clinical opportunity; that is, for using cells, genes, and proteins to rescue cardiac muscle cell number or in other ways promote more efficacious cardiac repair. Recent experimental studies and early-phase clinical trials lend credence to the visionary goal of enhancing cardiac repair as an achievable therapeutic target.